Big data study tracks Kids' bowel disease in korea
NCT ID NCT07520747
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times
Summary
This study uses health insurance claims data from Korea to count how many children under 18 have Crohn's disease or ulcerative colitis, and how their treatment changes as they grow. Researchers will look at patterns of medication use, hospital visits, and costs over several years. No new treatments are being tested—this is purely an observational study to gather information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 8,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will be selected from the health insurance review and assessment (HIRA) database and include pediatric participants, who have been newly diagnosed or previously with either crohn's disease (CD) or ulcerative colitis (UC).
- Ages
-
Up to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants with at least two outpatient or one inpatient diagnosis codes for the same disease type (either CD or UC) using international classification of diseases, tenth revision (ICD-10) codes (K50. X for CD and K51. X for UC) recorded as primary or the first secondary diagnosis, and the codes for rare and intractable disease registration program (V130 for CD, V131 for UC) during the index period * Participants who received at least one prescription for conventional pediatric inflammatory bowel disease (IBD)-related medications (for example, 5-aminosalicylic acids \[5-ASAs\], exclusive enteral nutrition \[EENs\], corticosteroids, immunomodulators, or biologic drugs) during the index period Exclusion Criteria: \- No specific exclusion criteria are defined in this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sungkyunkwan University Research and Business Foundation
RECRUITINGSuwon, 16419, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Can early symptom relief predict who stays on IBD biologic?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches